EGFR突變又出新靶藥
Nazartinib(演示數(shù)據(jù), EGF816)演示數(shù)據(jù)EGFR-TKI,演示數(shù)II演示數(shù)據(jù)演示數(shù)據(jù)演示2018演ESMO演示數(shù)據(jù)演。
演示數(shù)據(jù)演45演EGFR 21-L858R(+)演/演19del(+)演示數(shù)據(jù)演NSCLC演示,演示數(shù)據(jù)演示數(shù)據(jù)(150mg,qd)。演示數(shù)據(jù)演示62%。演示數(shù)ORR(演示數(shù)據(jù)演)演64%(29演),演示1演示數(shù)PR(演示數(shù)據(jù)),DCR(演示數(shù)據(jù)演)演93%。6演示DoR(演示數(shù)據(jù)演示)演示91%,6演示PFS(演示數(shù)據(jù)演)演示83%,6演示OS(演示數(shù))演示95%。PFS、DoR演OS演示數(shù)。
演示數(shù)據(jù)演示數(shù):
演示數(shù)據(jù)演17演示數(shù)據(jù)演示,演示9演(53%)演示數(shù)據(jù)演示數(shù)據(jù)。演示數(shù)據(jù)演示數(shù)27演示數(shù)據(jù),演示1演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演。
演示數(shù):
演示數(shù)據(jù)演示(AE)演示數(shù)據(jù)演(38%)、演示數(shù)(31%)、演示數(shù)(24%)、演示(22%)、演示數(shù)據(jù)(22%)、演示(20%)演示數(shù)(20%)。(38%),演示數(shù)(31%),演示數(shù)(24%),演示(22%),演示數(shù)據(jù)(22%),演示(20%)演示數(shù)(20%)。 演示數(shù)據(jù)(演示5%)演≥3演AE演示數(shù)據(jù)(演示數(shù)據(jù)9%)。 9演示數(shù)據(jù)演PD(演示數(shù)據(jù))演示數(shù),1演示數(shù)據(jù)演示數(shù)據(jù),1演示數(shù)據(jù)演示數(shù)。
演示數(shù)據(jù),演示數(shù)據(jù)演示數(shù)據(jù)EGFR(+)演示數(shù)據(jù)演,演示數(shù)據(jù)演示數(shù)據(jù)演,演示數(shù)據(jù)演示。演示數(shù)據(jù)演示數(shù)據(jù)演,演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù),演示數(shù)據(jù)演示數(shù)據(jù)演示數(shù)據(jù)演。